0001013762-16-001535.txt : 20160503
0001013762-16-001535.hdr.sgml : 20160503
20160503165958
ACCESSION NUMBER: 0001013762-16-001535
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160429
FILED AS OF DATE: 20160503
DATE AS OF CHANGE: 20160503
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DelMar Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001498382
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 990360497
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: SUITE 720-999 WEST BROADWAY
CITY: VANCOUVER
STATE: A1
ZIP: V5Z 1K5
BUSINESS PHONE: (604) 629-5989
MAIL ADDRESS:
STREET 1: SUITE 720-999 WEST BROADWAY
CITY: VANCOUVER
STATE: A1
ZIP: V5Z 1K5
FORMER COMPANY:
FORMER CONFORMED NAME: Berry Only Inc.
DATE OF NAME CHANGE: 20100805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Dennis M
CENTRAL INDEX KEY: 0001569520
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54801
FILM NUMBER: 161616235
MAIL ADDRESS:
STREET 1: 100 SAN MATEO DR
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
f4042916brown_delmar.xml
OWNERSHIP DOCUMENT
X0306
4
2016-04-29
0
0001498382
DelMar Pharmaceuticals, Inc.
DMPI
0001569520
Brown Dennis M
SUITE 720-999 WEST BROADWAY
VANCOUVER
A1
V5Z 1K5
BRITISH COLUMBIA, CANADA
1
1
0
0
Chief Scientific Officer
Series B Preferred Stock
2016-04-29
4
P
0
3000
8.00
A
2016-04-29
Common Stock
30000
3000
D
The Series B Preferred stock is convertible into such number of shares of common stock equal to the number of Preferred Shares to be converted, multiplied by the Stated Value of $8.00, divided by the Conversion Price in effect at the time of the conversion (the initial Conversion Price will be $0.80, subject to adjustment in the event of stock splits, stock dividends, and similar transactions).
The Reporting Person purchased Series B Preferred Stock from the Company in a private placement on April 29, 2016 (the "Private Placement").
The Series B Preferred Stock will automatically convert to common stock at the earlier of (a) the Company's lead product candidate, VAL-083, receiving Food and Drug Administration or European Medicines Agency approval (provided that, at the time of such approval, the closing bid price of the common stock is at least $2.00 (subject to adjustment for stock splits or stock dividends) or (b) five years from the final closing of the Private Placement.
/s/ Dennis Brown
2016-05-02